Creative Biolabs has invited Dr. Magnus A.G. Hoffmann to walk us through the application of hybrid mRNA technology in vaccine development, strategies for optimizing hybrid mRNA vaccines, and the use of this technology in developing pan-coronavirus vaccines.
Date and Time: November 20th, 2024, 2 PM–3 PM EST
Registration Link: https://mrna.creative-biolabs.com/eabr-nanoparticles-as-a-platform-technology-for-hybrid-mrna-vaccine.htm
During this webinar, we will explore the following key topics:
- Introduction on the importance of vaccines to protect against pandemics and the pros and cons of current vaccine strategies, including mRNA vaccines
- Description and development of the hybrid mRNA technology that combines features of mRNA- and protein nanoparticle-based vaccines
- In vivo evaluation of the hybrid mRNA technology for SARS-CoV-2 in mice, including new data on hybrid mRNA-based booster immunizations in pre-vaccinated mice
- Optimization strategies for hybrid mRNA vaccines, including preliminary data on new designs that enhance expression
- Application of the hybrid mRNA vaccine technology as a pan-coronavirus vaccine platform
